TRIUMPH-Outcomes: Cardiovascular Outcomes Trial (CVOT)

Study Overview

TRIUMPH-Outcomes is the largest trial in the retatrutide development program, enrolling approximately 10,000 participants to determine whether retatrutide reduces the risk of major adverse cardiovascular events (MACE) in adults with overweight or obesity and established cardiovascular disease. This type of cardiovascular outcomes trial (CVOT) has become increasingly important for obesity drugs following the landmark SELECT trial, which demonstrated cardiovascular risk reduction with semaglutide.

Scientific Rationale

The SELECT Paradigm Shift

The SELECT trial (2023) showed that semaglutide 2.4 mg reduced MACE by 20% in adults with overweight/obesity and cardiovascular disease — establishing a new paradigm where obesity drugs must demonstrate not just weight loss but cardiovascular event reduction.

Why Retatrutide May Show CV Benefits

Multiple mechanisms could contribute to cardiovascular risk reduction:

• Weight loss: Greater weight loss with retatrutide may translate to greater CV risk reduction
• GLP-1 receptor agonism: Established CV benefits from GLP-1 receptor agonists
• GIP receptor effects: Emerging evidence for anti-inflammatory vascular effects
• Glucagon receptor effects: May improve cardiac metabolism, reduce lipotoxicity, and enhance lipid profiles
• Blood pressure reduction: Consistent reductions of 4-8 mmHg in Phase 2
• Anti-inflammatory effects: Reduced CRP and inflammatory markers

Study Design

Population

Approximately 10,000 adults aged 45+ with:

• BMI ≥27 kg/m²
• Established atherosclerotic cardiovascular disease (prior MI, stroke, or peripheral arterial disease)

Design

Event-driven, randomized, double-blind, placebo-controlled trial. The study will continue until a pre-specified number of MACE events have occurred, which is expected to take 3-5 years.

Primary Endpoint

Time to first occurrence of MACE, defined as the composite of:

1. Cardiovascular death
2. Non-fatal myocardial infarction
3. Non-fatal stroke

Key Secondary Endpoints

• Individual MACE components
• All-cause mortality
• Heart failure hospitalization
• Body weight change
• HbA1c change (in participants with diabetes)

Timeline

• Enrollment: 2024-2026
• Treatment: 3-5 years (event-driven)
• Results: Expected 2028-2029

Significance

A positive result in TRIUMPH-Outcomes would be transformative for retatrutide’s commercial potential and clinical positioning:

• Would support a cardiovascular risk reduction indication
• Would drive payer coverage decisions (insurers increasingly require CVOT data)
• Would differentiate retatrutide from drugs without CV outcomes data
• Could establish triple agonism as superior to single or dual agonism for CV outcomes